

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:491052 CAPLUS  
DN 139:57948  
TI Liquid bisphosphonate formulations for bone disorders  
IN Daifotis, Anastasia G.; Leung, Albert T.; Bergquist, Paul A.; Denker, Andrew  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 59 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051373	A1	20030626	WO 2002-US38200	20021126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003139378	A1	20030724	US 2002-305868	20021126
	EP 1458400	A1	20040922	EP 2002-784653	20021126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRAI US 2001-340965P P 20011213  
WO 2002-US38200 W 20021126

AB The present invention relates to high dose oral liquid formulations of bisphosphonate and their methods of use to treat/prevent diseases to bone remodeling or bone disorders, such as for example, Paget's disease, osteoporosis, metastatic bone disease, hypercalcemia of malignancy, periprosthetic osteolysis, periodontal disease, arthritic conditions, and the like, while minimizing the potential for esophageal irritation and other adverse gastrointestinal effects. These methods comprise orally administering to a mammal the liquid pharmaceutical composition of at least 1 bisphosphonate, or a salt, as a unit dosage according to a continuous schedule having a once-weekly, twice-weekly, biweekly, twice-monthly, or monthly dosing interval. Thus, a formulation contained **alendronate monosodium trihydrate** 2.454, and sodium **citrate dihydrate** 21.18 mg/mL, NaOH and HCl qs to pH 6.8, and water qs to 1.00 mL.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:161293 CAPLUS

DN 132:199040

TI Sodium **alendronate** hydrates, processes for their manufacture, and pharmaceutical compositions containing them

IN Finkelstein, Nina; Lidor-Hadas, Ramy; Aronhime, Judith  
PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.

SO PCT Int. Appl., 56 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012517	A1	20000309	WO 1999-US19838	19990827
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,				

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341459 AA 20000309 CA 1999-2341459 19990827  
AU 9956988 A1 20000321 AU 1999-56988 19990827  
EP 1107974 A1 20010620 EP 1999-944004 19990827

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

US 6281381 B1 20010828 US 1999-384145 19990827

SI 20581 C 20011231 SI 1999-20070 19990827

BR 9913472 A 20020305 BR 1999-13472 19990827

EE 200100126 A 20020617 EE 2001-126 19990827

JP 2002523514 T2 20020730 JP 2000-567539 19990827

NZ 510682 A 20030926 NZ 1999-510682 19990827

ZA 2001001451 A 20020221 ZA 2001-1451 20010221

NO 2001000957 A 20010426 NO 2001-957 20010226

BG 105292 A 20011231 BG 2001-105292 20010226

LT 4888 B 20020225 LT 2001-16 20010226

LV 12720 B 20020220 LV 2001-26 20010405

US 2003065214 A1 20030403 US 2001-898756 20010703

US 6696601 B2 20040224

US 2004158098 A1 20040812 US 2003-751237 20031231

PRAI US 1998-98313P P 19980827  
US 1999-129743P P 19990416  
US 1999-144461P P 19990719  
US 1999-384145 A1 19990827  
WO 1999-US19838 W 19990827  
US 2001-898756 A1 20010703

AB New **hydrate** forms of **alendronate** sodium, having water content of approx. 1-12%, and processes for their manufacture, are disclosed. New crystalline forms of **alendronate** sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of **alendronate** sodium are suitable for incorporation into pharmaceutical compns. for combating bone resorption in bone diseases.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'HOME' ENTERED AT 13:44:13 ON 03 APR 2005)

FILE 'REGISTRY' ENTERED AT 13:44:29 ON 03 APR 2005

L1 0 S SODIUM ALENDRONATE DIHYDRATE/CN  
L2 1 S 260055-09-2/RN  
L3 0 S ABSOLUTE ETHANOL/CN  
L4 1 S ETHANOL/CN

FILE 'CAPLUS, CAOLD' ENTERED AT 13:52:21 ON 03 APR 2005

L5 0 S L2 AND ABSOLUTE ETHANOL  
L6 99 S ABSOLUTE ETHANOL  
L7 0 S L6 AND ALENDRON?  
L8 0 S L6 AND ?HYDRATE  
L9 0 S L6 AND MOLECULAR SIEVES  
L10 0 S L6 AND MOLECULAR SIEVE  
L11 1 S L6 AND MOLECULAR  
L12 5 S L6 AND DRYING  
L13 1 S L12 AND REFLUX?  
L14 2 S ?HYDROXYLBUTYLIDENE?  
L15 0 S L14 AND L6  
L16 1170 S ALENDRON?  
L17 75 S L16 AND ?HYDRATE  
L18 0 S L17 AND MOLECULAR SIEVE  
L19 0 S L17 AND L6  
L20 226476 S ETHANOL  
L21 2 S L17 AND L4  
L22 2 DUP REM L21 (0 DUPLICATES REMOVED)

(FILE 'HOME' ENTERED AT 13:44:13 ON 03 APR 2005)

FILE 'REGISTRY' ENTERED AT 13:44:29 ON 03 APR 2005

L1 0 S SODIUM ALENDRONATE DIHYDRATE/CN  
L2 1 S 260055-09-2/RN  
L3 0 S ABSOLUTE ETHANOL/CN  
L4 1 S ETHANOL/CN

FILE 'CAPLUS, CAOLD' ENTERED AT 13:52:21 ON 03 APR 2005

L5 0 S L2 AND ABSOLUTE ETHANOL  
L6 99 S ABSOLUTE ETHANOL  
L7 0 S L6 AND ALENDRON?  
L8 0 S L6 AND ?HYDRATE  
L9 0 S L6 AND MOLECULAR SIEVES  
L10 0 S L6 AND MOLECULAR SIEVE  
L11 1 S L6 AND MOLECULAR  
L12 5 S L6 AND DRYING  
L13 1 S L12 AND REFLUX?  
L14 2 S ?HYDROXYLBUTYLIDENE?  
L15 0 S L14 AND L6  
L16 1170 S ALENDRON?  
L17 75 S L16 AND ?HYDRATE  
L18 0 S L17 AND MOLECULAR SIEVE  
L19 0 S L17 AND L6  
L20 226476 S ETHANOL  
L21 2 S L17 AND L4  
L22 2 DUP REM L21 (0 DUPLICATES REMOVED)  
L23 8 S L6 AND REFLUX?  
L24 8 DUP REM L23 (0 DUPLICATES REMOVED)  
L25 8 S L24 NOT L22  
L26 8 S L24 NOT L14  
L27 0 S L6 AND PHOSPHONIC  
L28 1 S L6 AND PHOSPHON?  
L29 54998 F HIS